antiviral and associated therapy - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.01 [0.94, 1.08]< 10%19 studies (19/-)41.0 %some concernlow moderatecrucial-
death or transfer to ICU 1.09 [0.99, 1.20]< 10%1 study (1/-)4.0 %NAnot evaluable crucial-
deaths 0.98 [0.93, 1.03]< 10%71 studies (71/-)79.5 %some concerncritical moderatecrucial-
deaths (time to event analysis only) 0.93 [0.83, 1.04]< 148%12 studies (12/-)89.9 %some concerncritical moderatecrucial-
clinical deterioration 0.97 [0.77, 1.22]< 110%15 studies (15/-)61.3 %some concernlow moderateimportant-
clinical improvement 1.16 [1.00, 1.33]> 149%20 studies (20/-)97.8 %some concernlow moderateimportant-
clinical improvement (14-day) 1.07 [0.89, 1.27]> 148%17 studies (17/-)76.1 %some concernlow moderateimportant-
clinical improvement (21-day) 2.09 [0.04, 119.96]> 10%1 study (1/-)63.7 %NAnot evaluable important-
clinical improvement (28-day) 1.24 [1.03, 1.50]> 154%9 studies (9/-)98.8 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.16 [0.97, 1.38]> 148%14 studies (14/-)95.2 %some concerncritical moderateimportant-
clinical improvement (time to event analysis only) 1.19 [1.08, 1.32]> 130%15 studies (15/-)100.0 %some concernlow moderateimportant-
death or ventilation 1.02 [0.95, 1.10]< 120%8 studies (8/-)28.5 %some concernnot evaluable moderateimportant-
hospital discharge 0.99 [0.93, 1.06]> 139%15 studies (15/-)43.1 %some concernlow moderateimportant-
hospitalization 0.25 [0.08, 0.83]< 10%2 studies (2/-)98.8 %NAnot evaluable important-
mechanical ventilation 0.89 [0.72, 1.10]< 134%22 studies (22/-)86.1 %some concerncritical moderateimportant-
mechanical ventilation (time to event analysis only) 0.06 [0.01, 0.83]< 10%1 study (1/-)98.2 %NAnot evaluable important-
radiologic improvement (14-day) 1.17 [0.42, 3.26]> 116%3 studies (3/-)62.1 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 0.40 [0.02, 6.97]> 177%3 studies (3/-)26.9 %some concernnot evaluable moderateimportant-
viral clearance 1.14 [0.89, 1.46]> 153%14 studies (14/-)85.4 %some concernlow moderateimportant-
viral clearance (time to event analysis only) 1.09 [0.81, 1.46]> 154%6 studies (6/-)71.4 %some concernnot evaluable moderateimportant-
viral clearance by day 14 1.23 [0.79, 1.91]> 113%10 studies (10/-)82.2 %some concernlow moderateimportant-
viral clearance by day 7 1.15 [0.86, 1.54]> 162%11 studies (11/-)83.4 %some concernlow moderateimportant-
ICU admission 0.88 [0.67, 1.16]< 113%13 studies (13/-)81.3 %some concernlow moderatenon important-
off oxygenation 0.98 [0.64, 1.51]> 10%1 study (1/-)46.4 %NAnot evaluable non important-
recovery 1.09 [0.95, 1.26]> 147%5 studies (5/-)89.0 %some concernnot evaluable moderatenon important-

safety endpoints 00

AE leading to drug discontinuation 2.43 [0.79, 7.45]< 10%1 study (1/-)6.0 %NAnot evaluable important-
cardiac arrest 1.92 [0.35, 10.49]< 10%1 study (1/-)22.7 %NAnot evaluable important-
related SAE (TRSAE) 1.24 [0.50, 3.11]< 10%1 study (1/-)32.0 %NAnot evaluable important-
serious adverse events 0.85 [0.71, 1.01]< 10%21 studies (21/-)96.6 %some concernlow moderateimportant-
acute kidney injury 1.18 [0.44, 3.18]< 10%1 study (1/-)37.2 %NAnot evaluable non important-
adverse events 1.89 [1.44, 2.48]< 166%21 studies (21/-)0.0 %some concerncritical moderatenon important-
arrhythmia 0.91 [0.72, 1.15]< 10%3 studies (3/-)78.1 %some concernnot evaluable moderatenon important-
deep vein thrombosis 0.62 [0.23, 1.64]< 10%2 studies (2/-)83.1 %some concernnot evaluable moderatenon important-
elevated liver enzymes 0.95 [0.29, 3.10]< 184%3 studies (3/-)53.6 %some concernnot evaluable moderatenon important-
hyperbilirubinemia 0.97 [0.48, 1.93]< 10%2 studies (2/-)53.8 %lownot evaluable highnon important-
long QT 2.39 [0.24, 23.87]< 180%2 studies (2/-)23.0 %some concernnot evaluable moderatenon important-
pulmonary embolism 0.82 [0.20, 3.29]< 10%2 studies (2/-)61.1 %some concernnot evaluable moderatenon important-
renal impairment 1.26 [0.95, 1.67]< 10%4 studies (4/-)5.6 %some concernnot evaluable moderatenon important-
severe adverse events 1.10 [0.07, 18.09]< 10%2 studies (2/-)47.4 %highnot evaluable lownon important-

AE of interest endpoints 00

Thromboembolic events 0.89 [0.31, 2.55]< 10%1 study (1/-)58.6 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.